Maze Therapeutics, Inc. (MAZE) Stock Price & Analysis
Maze Therapeutics, Inc. (MAZE) fell 0.04% to USD 27.68 as of July 26, 2026 at 05:58 UTC, according to Nexqual real-time market data.
MAZE last closed at USD 27.69; the session ranged USD 27.39–28.12 on volume of 157,328 shares. Market capitalization is $1.53B, with a 52-week range of USD 12.81–53.65 (NGM). Source: Nexqual, July 26, 2026 at 05:58 UTC.
Key Statistics (as of July 26, 2026 at 05:58 UTC)
| Price | USD 27.68 |
|---|---|
| Change | ▼ 0.04% (down) |
| Previous Close | USD 27.69 |
| Open | USD 27.87 |
| Day Range | USD 27.39 – 28.12 |
| 52-Week Range | USD 12.81 – 53.65 |
| Volume | 157,328 shares |
| Market Cap | $1.53B |
| Exchange | NGM |
Technical Analysis (MAZE)
Nexqual's technical model rates MAZE "NEUTRAL" based on 3 bullish and 3 bearish signals across 125 daily candles, as of July 26, 2026 at 05:58 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 47.62 (neutral) |
| vs SMA50 | Above (USD 27.03) |
| MACD | 0.2 (positive) |
Analyst Ratings (MAZE)
Wall Street analysts rate MAZE "Strong Buy" based on 11 analysts, with a mean price target of USD 62.55 (range USD 46–110), per Nexqual as of July 26, 2026 at 05:58 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 11 |
| Mean Target | USD 62.55 |
| High Target | USD 110 |
| Low Target | USD 46 |
| Buy / Hold / Sell | 12 / 0 / 0 |
Earnings (MAZE)
| Next Earnings Date | 2026-08-12 |
|---|---|
| EPS Estimate | USD -0.7 |
| Revenue Estimate | $1.82M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -0.65 vs est -0.69 ▲ beat |
| 2025-09-30 | USD -0.66 vs est -0.69 ▲ beat |
| 2025-06-30 | USD -0.77 vs est -1.16 ▲ beat |
Source: Nexqual, July 26, 2026 at 05:58 UTC.
Financials & Fundamentals (MAZE)
| Total Revenue | $20.00M |
|---|---|
| Gross Margin | +100.00% |
| Operating Margin | -132.76% |
| Profit Margin | +0.00% |
| ROE | -38.67% |
| Debt / Equity | 17.92 |
| Current Ratio | 17.88 |
| Total Cash | $352.38M |
| Total Debt | $61.22M |
| Free Cash Flow | $-81.70M |
Source: Nexqual, July 26, 2026 at 05:58 UTC.
Financial Health Score (MAZE)
Nexqual rates Maze Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of July 26, 2026 at 05:58 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $352M cash vs $61M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$122M |
| Efficiency | Critical — ROE -39%, ROA -22.3% |
Ownership (MAZE)
| Insider Ownership | +1.46% |
|---|---|
| Institutional Ownership | +96.53% |
| Shares Outstanding | 55.35M |
| Float | 37.25M |
| Short % of Float | +11.25% |
Source: Nexqual, July 26, 2026 at 05:58 UTC.
Leadership (MAZE)
Maze Therapeutics, Inc. is led by Jason V. Coloma M.B.A., M.P.H. (age 49), CEO & Director, per Nexqual as of July 26, 2026 at 05:58 UTC.
| CEO & Director | Jason V. Coloma M.B.A., M.P.H. (age 49) |
|---|---|
| CFO & Principal Accounting Officer | Misbah Tahir (age 50) |
| President of Research & Development and Chief Medical Officer | Harold S. Bernstein (age 65) |
| Vice President of R & D Infrastructure and Operations | Vipin Vijayakumar |
| Senior Vice President of Human Resources | Matt Krause |
Major Backers & Investors (MAZE)
Notable institutional backers of Maze Therapeutics, Inc. include Frazier Life Sciences Management, L.P. , TRV GP IV, LLC, Arch Venture Management, Llc, according to Nexqual as of July 26, 2026 at 05:58 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Frazier Life Sciences Management, L.P. | 8.25% |
| TRV GP IV, LLC | 8.08% |
| Arch Venture Management, Llc | 7.44% |
| Deep Track Capital, Lp | 6.28% |
| Janus Henderson Group PLC | 5.17% |
| Paradigm Biocapital Advisors LP | 4.96% |
| a16z Capital Management, L.L.C. | 3.08% |
| Venrock Adviser, LLC | 2.89% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 6.93% |
| Vanguard Group | 5.11% |
Source: Nexqual, July 26, 2026 at 05:58 UTC.
From Maze Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-25)
Key Strengths & Strategy (as disclosed to the SEC)
- Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States.
- Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease.
- The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease.
- It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SION | Sionna Therapeutics, Inc. | USD 45.7 | ▲ 1.49% |
| RAPP | Rapport Therapeutics, Inc. | USD 40.68 | ▼ 1.57% |
| MBX | MBX Biosciences, Inc. | USD 62 | ▲ 6.35% |
| BCAX | Bicara Therapeutics Inc. | USD 27.02 | ▼ 3.36% |
| DNTH | Dianthus Therapeutics, Inc. | USD 103.87 | ▲ 1.08% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 05:58 UTC. This page is informational and not investment advice.